Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Study commences on chronic disease caused by trauma

Aethlon Medical : 21 January, 2016  (Company News)
The detection and diagnosis of chronic traumatic encephalopathy associated with sports and military injuries is the subject of a new clinical study by Aethlon Medical
Study commences on chronic disease caused by trauma


Exosome Sciences and Aethlon Medical have agreed to participate in a clinical research study to establish methods for detecting and diagnosing chronic traumatic encephalopathy (CTE) during life as well as examining risk factors for CTE. CTE is a disease of the brain often found in athletes, military veterans, and others with a history of repetitive head impacts. At present, CTE can only be definitively diagnosed through post-mortem examination of brain tissue.



The research study will be conducted under a $16 million grant that the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) has awarded to researchers from Boston University, the Cleveland Clinic, Banner Alzheimer's Institute and Brigham and Women's Hospital in Boston. Overall, the project will involve a group of approximately 50 investigators, representing 17 research institutions. Exosome Sciences has agreed to test an exosomal tau biomarker (TauSome) that it has been advancing as a blood-based candidate to diagnose CTE.



"We are truly grateful that our colleagues at the Boston University CTE Center have expanded our opportunity to validate our Tausome biomarker as a candidate to detect and monitor CTE in living individuals," stated Jim Joyce, Executive Chairman at Exosome Sciences and Chairman and CEO of Aethlon Medical.



Following its participation in the Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) study conducted by the Boston University CTE Centre, Exosome Sciences also disclosed that it has agreed to provide follow-on TauSome testing to former NFL players who participated in that study. The DETECT study was the first research project on CTE to be funded by the NIH, with support from NINDS, the National Institute on Aging (NIA), and the National Institute of Child Health and Human Development (NICHD).  The DETECT study enrolled former NFL players (ages 40-69) and same-age "control" athletes who played non-contact sports. A manuscript which details TauSome (exosomal tau) data resulting from the DETECT study is pending publication.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo